Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zegarra-Moro, O. L.
Right arrow Articles by Tindall, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zegarra-Moro, O. L.
Right arrow Articles by Tindall, D. J.
[Cancer Research 62, 1008-1013, February 15, 2002]
© 2002 American Association for Cancer Research

Advances in Brief

Disruption of Androgen Receptor Function Inhibits Proliferation of Androgen-refractory Prostate Cancer Cells1

Ofelia L. Zegarra-Moro, Lucy J. Schmidt, Haojie Huang and Donald J. Tindall2

Departments of Biochemistry and Molecular Biology and Urology, Mayo Clinic, Rochester, Minnesota 55905

Prostate cancer cells depend on androgens and the androgen receptor (AR) for survival. However, after androgen ablation therapy, tumors relapse to an androgen-refractory state. To determine whether the androgen receptor is critical for proliferation of androgen-refractory prostate cancer cells, we disrupted the activity of the androgen receptor with an antibody and an AR mRNA hammerhead ribozyme in the following cell lines: LNCaP (androgen-sensitive), LNCaP-Rf and LNCaP-C4 (androgen-refractory), and DU-145 (androgen-insensitive). Microinjection of either antibody or ribozyme inhibited proliferation of androgen-refractory cells. These findings demonstrate that the AR is critical for proliferation of androgen-refractory cells, even in the absence of androgens.




This article has been cited by other articles:


Home page
 J. Cell Sci.Home page
H. Wang, D. Sun, P. Ji, J. Mohler, and L. Zhu
An AR-Skp2 pathway for proliferation of androgen-dependent prostate-cancer cells
J. Cell Sci., August 1, 2008; 121(15): 2578 - 2587.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
L. S. Lyons, S. Rao, W. Balkan, J. Faysal, C. A. Maiorino, and K. L. Burnstein
Ligand-Independent Activation of Androgen Receptors by Rho GTPase Signaling in Prostate Cancer
Mol. Endocrinol., March 1, 2008; 22(3): 597 - 608.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
S. Ko, L. Shi, S. Kim, C. S. Song, and B. Chatterjee
Interplay of Nuclear Factor-{kappa}B and B-myb in the Negative Regulation of Androgen Receptor Expression by Tumor Necrosis Factor {alpha}
Mol. Endocrinol., February 1, 2008; 22(2): 273 - 286.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
J. H. Suh, E.-Y. Gong, J. B. Kim, I.-K. Lee, H.-S. Choi, and K. Lee
Sterol Regulatory Element-Binding Protein-1c Represses the Transactivation of Androgen Receptor and Androgen-Dependent Growth of Prostatic Cells
Mol. Cancer Res., February 1, 2008; 6(2): 314 - 324.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. H. Suh, M. Shong, H.-S. Choi, and K. Lee
CR6-Interacting Factor 1 Represses the Transactivation of Androgen Receptor by Direct Interaction
Mol. Endocrinol., January 1, 2008; 22(1): 33 - 46.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
H. Neuwirt, M. Puhr, I. T Cavarretta, M. Mitterberger, A. Hobisch, and Z. Culig
Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion
Endocr. Relat. Cancer, December 1, 2007; 14(4): 1007 - 1019.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
S. M. Dehm and D. J. Tindall
Androgen Receptor Structural and Functional Elements: Role and Regulation in Prostate Cancer
Mol. Endocrinol., December 1, 2007; 21(12): 2855 - 2863.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. M. Dehm, K. M. Regan, L. J. Schmidt, and D. J. Tindall
Selective Role of an NH2-Terminal WxxLF Motif for Aberrant Androgen Receptor Activation in Androgen Depletion Independent Prostate Cancer Cells
Cancer Res., October 15, 2007; 67(20): 10067 - 10077.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
C.-T. Wu, W.-C. Chen, S.-K. Liao, C.-L. Hsu, K.-D. Lee, and M.-F. Chen
The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy
Endocr. Relat. Cancer, September 1, 2007; 14(3): 633 - 643.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. M. Shen and C. Abate-Shen
Pten Inactivation and the Emergence of Androgen-Independent Prostate Cancer
Cancer Res., July 15, 2007; 67(14): 6535 - 6538.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
Y. Xie, D. W. Wolff, M.-F. Lin, and Y. Tu
Vasoactive Intestinal Peptide Transactivates the Androgen Receptor through a Protein Kinase A-Dependent Extracellular Signal-Regulated Kinase Pathway in Prostate Cancer LNCaP Cells
Mol. Pharmacol., July 1, 2007; 72(1): 73 - 85.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
G. Deep and R. Agarwal
Chemopreventive Efficacy of Silymarin in Skin and Prostate Cancer
Integr Cancer Ther, June 1, 2007; 6(2): 130 - 145.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
K. Tamura, M. Furihata, T. Tsunoda, S. Ashida, R. Takata, W. Obara, H. Yoshioka, Y. Daigo, Y. Nasu, H. Kumon, et al.
Molecular Features of Hormone-Refractory Prostate Cancer Cells by Genome-Wide Gene Expression Profiles
Cancer Res., June 1, 2007; 67(11): 5117 - 5125.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Miki, B. Furusato, H. Li, Y. Gu, H. Takahashi, S. Egawa, I. A. Sesterhenn, D. G. McLeod, S. Srivastava, and J. S. Rhim
Identification of Putative Stem Cell Markers, CD133 and CXCR4, in hTERT-Immortalized Primary Nonmalignant and Malignant Tumor-Derived Human Prostate Epithelial Cell Lines and in Prostate Cancer Specimens
Cancer Res., April 1, 2007; 67(7): 3153 - 3161.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W. Fan, T. Yanase, H. Morinaga, T. Okabe, M. Nomura, H. Daitoku, A. Fukamizu, S. Kato, R. Takayanagi, and H. Nawata
Insulin-like Growth Factor 1/Insulin Signaling Activates Androgen Signaling through Direct Interactions of Foxo1 with Androgen Receptor
J. Biol. Chem., March 9, 2007; 282(10): 7329 - 7338.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Guo, C. Jiang, Z. Wang, H.-J. Lee, H. Hu, B. Malewicz, H.-J. Lee, J.-H. Lee, N.-I. Baek, J.-H. Jeong, et al.
A novel class of pyranocoumarin anti-androgen receptor signaling compounds
Mol. Cancer Ther., March 1, 2007; 6(3): 907 - 917.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
F. Alimirah, J. Chen, F. J. Davis, and D. Choubey
IFI16 in Human Prostate Cancer
Mol. Cancer Res., March 1, 2007; 5(3): 251 - 259.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Q. Ji, L. Chang, F. Z. Stanczyk, M. Ookhtens, A. Sherrod, and A. Stolz
Impaired Dihydrotestosterone Catabolism in Human Prostate Cancer: Critical Role of AKR1C2 as a Pre-Receptor Regulator of Androgen Receptor Signaling
Cancer Res., February 1, 2007; 67(3): 1361 - 1369.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. P. Pelley, K. Chinnakannu, S. Murthy, F. M. Strickland, M. Menon, Q. P. Dou, E. R. Barrack, and G. P.-V. Reddy
Calmodulin-Androgen Receptor (AR) Interaction: Calcium-Dependent, Calpain-Mediated Breakdown of AR in LNCaP Prostate Cancer Cells
Cancer Res., December 15, 2006; 66(24): 11754 - 11762.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. U. Agoulnik, A. Vaid, M. Nakka, M. Alvarado, W. E. Bingman III, H. Erdem, A. Frolov, C. L. Smith, G. E. Ayala, M. M. Ittmann, et al.
Androgens Modulate Expression of Transcription Intermediary Factor 2, an Androgen Receptor Coactivator whose Expression Level Correlates with Early Biochemical Recurrence in Prostate Cancer
Cancer Res., November 1, 2006; 66(21): 10594 - 10602.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
I. V. Litvinov, D. J. Vander Griend, L. Antony, S. Dalrymple, A. M. De Marzo, C. G. Drake, and J. T. Isaacs
Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells
PNAS, October 10, 2006; 103(41): 15085 - 15090.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
L. Jia, H. C. Shen, M. Wantroba, O. Khalid, G. Liang, Q. Wang, E. Gentzschein, J. K. Pinski, F. Z. Stanczyk, P. A. Jones, et al.
Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells.
Mol. Cell. Biol., October 1, 2006; 26(19): 7331 - 7341.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
L.G. Wang, X.M. Liu, and J.W. Chiao
Repression of androgen receptor in prostate cancer cells by phenethyl isothiocyanate
Carcinogenesis, October 1, 2006; 27(10): 2124 - 2132.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. M. Dehm and D. J. Tindall
Ligand-independent Androgen Receptor Activity Is Activation Function-2-independent and Resistant to Antiandrogens in Androgen Refractory Prostate Cancer Cells
J. Biol. Chem., September 22, 2006; 281(38): 27882 - 27893.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
P Singh, A Uzgare, I Litvinov, S R Denmeade, and J T Isaacs
Combinatorial androgen receptor targeted therapy for prostate cancer.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 653 - 666.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
X. Yuan, T. Li, H. Wang, T. Zhang, M. Barua, R. A. Borgesi, G. J. Bubley, M. L. Lu, and S. P. Balk
Androgen Receptor Remains Critical for Cell-Cycle Progression in Androgen-Independent CWR22 Prostate Cancer Cells
Am. J. Pathol., August 1, 2006; 169(2): 682 - 696.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Q. Xia, J. Sung, W. Chowdhury, C.-l. Chen, N. Hoti, S. Shabbeer, M. Carducci, and R. Rodriguez
Chronic Administration of Valproic Acid Inhibits Prostate Cancer Cell Growth In vitro and In vivo.
Cancer Res., July 15, 2006; 66(14): 7237 - 7244.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. S. Bhattacharyya, A. V. Krishnan, S. Swami, and D. Feldman
Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells.
Mol. Cancer Ther., June 1, 2006; 5(6): 1539 - 1549.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
L. M. Butler, M. M. Centenera, P. J. Neufing, G. Buchanan, C. S. Y. Choong, C. Ricciardelli, K. Saint, M. Lee, A. Ochnik, M. Yang, et al.
Suppression of Androgen Receptor Signaling in Prostate Cancer Cells by an Inhibitory Receptor Variant
Mol. Endocrinol., May 1, 2006; 20(5): 1009 - 1024.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. He, R. T. Gampe Jr., A. T. Hnat, J. L. Faggart, J. T. Minges, F. S. French, and E. M. Wilson
Probing the Functional Link between Androgen Receptor Coactivator and Ligand-binding Sites in Prostate Cancer and Androgen Insensitivity
J. Biol. Chem., March 10, 2006; 281(10): 6648 - 6663.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Stanbrough, G. J. Bubley, K. Ross, T. R. Golub, M. A. Rubin, T. M. Penning, P. G. Febbo, and S. P. Balk
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.
Cancer Res., March 1, 2006; 66(5): 2815 - 2825.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
D. Gioeli, B. E. Black, V. Gordon, A. Spencer, C. T. Kesler, S. T. Eblen, B. M. Paschal, and M. J. Weber
Stress Kinase Signaling Regulates Androgen Receptor Phosphorylation, Transcription, and Localization
Mol. Endocrinol., March 1, 2006; 20(3): 503 - 515.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Jiang, H.-J. Lee, G.-x. Li, J. Guo, B. Malewicz, Y. Zhao, E.-O. Lee, H.-J. Lee, J.-H. Lee, M.-S. Kim, et al.
Potent Antiandrogen and Androgen Receptor Activities of an Angelica gigas-Containing Herbal Formulation: Identification of Decursin as a Novel and Active Compound with Implications for Prevention and Treatment of Prostate Cancer
Cancer Res., January 1, 2006; 66(1): 453 - 463.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S. Veeramani, T.-C. Yuan, S.-J. Chen, F.-F. Lin, J. E Petersen, S. Shaheduzzaman, S. Srivastava, R. G MacDonald, and M.-F. Lin
Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer
Endocr. Relat. Cancer, December 1, 2005; 12(4): 805 - 822.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. I. Scher and C. L. Sawyers
Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis
J. Clin. Oncol., November 10, 2005; 23(32): 8253 - 8261.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Yang, S. Xie, Md. S. Jamaluddin, S. Altuwaijri, J. Ni, E. Kim, Y.-T. Chen, Y.-C. Hu, L. Wang, K.-H. Chuang, et al.
Induction of Androgen Receptor Expression by Phosphatidylinositol 3-Kinase/Akt Downstream Substrate, FOXO3a, and Their Roles in Apoptosis of LNCaP Prostate Cancer Cells
J. Biol. Chem., September 30, 2005; 280(39): 33558 - 33565.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Mohapatra, B. Chu, X. Zhao, and W.J. Pledger
Accumulation of p53 and Reductions in XIAP Abundance Promote the Apoptosis of Prostate Cancer Cells
Cancer Res., September 1, 2005; 65(17): 7717 - 7723.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. U. Agoulnik, A. Vaid, W. E. Bingman III, H. Erdeme, A. Frolov, C. L. Smith, G. Ayala, M. M. Ittmann, and N. L. Weigel
Role of SRC-1 in the Promotion of Prostate Cancer Cell Growth and Tumor Progression
Cancer Res., September 1, 2005; 65(17): 7959 - 7967.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. Chen, S. Meng, H. Wang, P. Bali, W. Bai, B. Li, P. Atadja, K. N. Bhalla, and J. Wu
Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824
Mol. Cancer Ther., September 1, 2005; 4(9): 1311 - 1319.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Y. Zhang, X.-W. Wang, D. Jelovac, T. Nakanishi, M.-h. Yu, D. Akinmade, O. Goloubeva, D. D. Ross, A. Brodie, and A. W. Hamburger
The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells
PNAS, July 12, 2005; 102(28): 9890 - 9895.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Dong, H. Zhang, A. C. Gao, J. R. Marshall, and C. Ip
Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers
Mol. Cancer Ther., July 1, 2005; 4(7): 1047 - 1055.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
Z Culig, H Steiner, G Bartsch, and A Hobisch
Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours
Endocr. Relat. Cancer, June 1, 2005; 12(2): 229 - 244.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Bonham, J. Posakony, I. Coleman, B. Montgomery, J. Simon, and P. S. Nelson
Characterization of Chemical Constituents in Scutellaria baicalensis with Antiandrogenic and Growth-Inhibitory Activities toward Prostate Carcinoma
Clin. Cancer Res., May 15, 2005; 11(10): 3905 - 3914.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Liu, S. Majumder, W. McCall, C. I. Sartor, J. L. Mohler, C. W. Gregory, H. S. Earp, and Y. E. Whang
Inhibition of HER-2/neu Kinase Impairs Androgen Receptor Recruitment to the Androgen Responsive Enhancer
Cancer Res., April 15, 2005; 65(8): 3404 - 3409.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
M. E. Wright, D. K. Han, and R. Aebersold
Mass Spectrometry-based Expression Profiling of Clinical Prostate Cancer
Mol. Cell. Proteomics, April 1, 2005; 4(4): 545 - 554.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
X. Liao, S. Tang, J. B. Thrasher, T. L. Griebling, and B. Li
Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer
Mol. Cancer Ther., April 1, 2005; 4(4): 505 - 515.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. A. Kasbohm, R. Guo, C. W. Yowell, G. Bagchi, P. Kelly, P. Arora, P. J. Casey, and Y. Daaka
Androgen Receptor Activation by Gs Signaling in Prostate Cancer Cells
J. Biol. Chem., March 25, 2005; 280(12): 11583 - 11589.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T.-L. Cha, L. Qiu, C.-T. Chen, Y. Wen, and M.-C. Hung
Emodin Down-Regulates Androgen Receptor and Inhibits Prostate Cancer Cell Growth
Cancer Res., March 15, 2005; 65(6): 2287 - 2295.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. W. Gregory, Y. E. Whang, W. McCall, X. Fei, Y. Liu, L. A. Ponguta, F. S. French, E. M. Wilson, and H. S. Earp III
Heregulin-Induced Activation of HER2 and HER3 Increases Androgen Receptor Transactivation and CWR-R1 Human Recurrent Prostate Cancer Cell Growth
Clin. Cancer Res., March 1, 2005; 11(5): 1704 - 1712.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
C.-L. Hsu, Y.-L. Chen, H.-J. Ting, W.-J. Lin, Z. Yang, Y. Zhang, L. Wang, C.-T. Wu, H.-C. Chang, S. Yeh, et al.
Androgen Receptor (AR) NH2- and COOH-Terminal Interactions Result in the Differential Influences on the AR-Mediated Transactivation and Cell Growth
Mol. Endocrinol., February 1, 2005; 19(2): 350 - 361.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Nishiyama, Y. Hashimoto, and K. Takahashi
The Influence of Androgen Deprivation Therapy on Dihydrotestosterone Levels in the Prostatic Tissue of Patients with Prostate Cancer
Clin. Cancer Res., November 1, 2004; 10(21): 7121 - 7126.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Unni, S. Sun, B. Nan, M. J. McPhaul, B. Cheskis, M. A. Mancini, and M. Marcelli
Changes in Androgen Receptor Nongenotropic Signaling Correlate with Transition of LNCaP Cells to Androgen Independence
Cancer Res., October 1, 2004; 64(19): 7156 - 7168.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
H. I Scher, G. Buchanan, W. Gerald, L. M Butler, and W. D Tilley
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer
Endocr. Relat. Cancer, September 1, 2004; 11(3): 459 - 476.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. W. Gregory, X. Fei, L. A. Ponguta, B. He, H. M. Bill, F. S. French, and E. M. Wilson
Epidermal Growth Factor Increases Coactivation of the Androgen Receptor in Recurrent Prostate Cancer
J. Biol. Chem., February 20, 2004; 279(8): 7119 - 7130.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
L. Barzon, M. Boscaro, and G. Palu
Endocrine Aspects of Cancer Gene Therapy
Endocr. Rev., February 1, 2004; 25(1): 1 - 44.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. L. Mohler, C. W. Gregory, O. H. Ford III, D. Kim, C. M. Weaver, P. Petrusz, E. M. Wilson, and F. S. French
The Androgen Axis in Recurrent Prostate Cancer
Clin. Cancer Res., January 15, 2004; 10(2): 440 - 448.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
E. Cifuentes, J. M. Mataraza, B. A. Yoshida, M. Menon, D. B. Sacks, E. R. Barrack, and G. P.-V. Reddy
Physical and functional interaction of androgen receptor with calmodulin in prostate cancer cells
PNAS, January 13, 2004; 101(2): 464 - 469.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. Holzbeierlein, P. Lal, E. LaTulippe, A. Smith, J. Satagopan, L. Zhang, C. Ryan, S. Smith, H. Scher, P. Scardino, et al.
Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy Resistance
Am. J. Pathol., January 1, 2004; 164(1): 217 - 227.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. E. Wright, M.-J. Tsai, and R. Aebersold
Androgen Receptor Represses the Neuroendocrine Transdifferentiation Process in Prostate Cancer Cells
Mol. Endocrinol., September 1, 2003; 17(9): 1726 - 1737.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. L. Xu, Y. Shi, G. Petrovics, C. Sun, M. Makarem, W. Zhang, I. A. Sesterhenn, D. G. McLeod, L. Sun, J. W. Moul, et al.
PMEPA1, an Androgen-regulated NEDD4-binding Protein, Exhibits Cell Growth Inhibitory Function and Decreased Expression during Prostate Cancer Progression
Cancer Res., August 1, 2003; 63(15): 4299 - 4304.
[Abstract] [Full Text] [PDF]